Recruiting NCT05264259
New Therapeutic Approach Against BK Virus Infection Based on Monoclonal Antibodies
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- This is an observational study: the protocol does not assign a study treatment.
- Who it may be relevant to
- Registry conditions: BK Virus Infection. Basic parameters: from 18 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- France
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Overview
BK virus (BKV) infection has a major negative impact on transplant recipients. No BKV-specific antiviral therapy is available, so there is an urgent need to develop new anti-BKV preventive and therapeutic strategies.
Primary outcome measures
- Ability of the isolated monoclonal antibodies to neutralize all 3 BKV genotypes [Time frame: 5 years]
Eligibility criteria
Inclusion criteria
- BK positive
- adult
- ok to participed to research
Exclusion criteria
- under guardianship
- under curatorship
- opposed to research
- deprived of liberty
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Observational model
- Cohort
Study locations
France · 1 center
- Service de Virologie - CHU Strasbourg - France — Strasbourg
Identifiers
NCT: NCT05264259 · 8521